Nephroprotective effects of ferulic acid, Z-ligustilide and E-ligustilide isolated from angelica sinensis against cisplatin toxicity in vitro

Toxicology in Vitro

Volumn 29, Issue 3, 2015, Pages 458-467

  Bunel, Valérian ^a   Antoine, Marie Hélène ^a   Nortier, Joëlle ^a   Duez, Pierre ^a,b   Stévigny, Caroline ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY OF MONS   (Belgium)

Author keywords

Cisplatin; Ferulic acid; HK 2 cells; Ligustilide; Nephroprotection; Regeneration

Indexed keywords

BETA CATENIN; CISPLATIN; E LIGUSTILIDE; FERULIC ACID; LIGUSTILIDE; UNCLASSIFIED DRUG; Z LIGUSTILIDE; ANTINEOPLASTIC AGENT; COLLAGEN; COUMARIC ACID; GAMMA BUTYROLACTONE; PLANT EXTRACT; PROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE;

ACUTE KIDNEY FAILURE; ANGELICA SINENSIS; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; NEPHROTOXICITY; NEUROPROTECTION; OXIDATIVE STRESS; PLANT ROOT; PROTEIN LOCALIZATION; ACUTE KIDNEY INJURY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; KIDNEY DISEASES; METABOLISM; WOUND HEALING;

ANGELICA SINENSIS;

4-BUTYROLACTONE; ACUTE KIDNEY INJURY; ANGELICA SINENSIS; ANTINEOPLASTIC AGENTS; CELL LINE; CISPLATIN; COLLAGEN; COUMARIC ACIDS; HUMANS; IN VITRO TECHNIQUES; KIDNEY DISEASES; PLANT EXTRACTS; PROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES; WOUND HEALING;

EID: 84921305387     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2014.12.017     Document Type: Article

References (52)

1. Anonymous, 2011. FlowJo, data analysis software for flow cytometry, In: Inc., T.S. (Ed.), FlowJo Advanced Tutorial, 7.6.2 ed., Tree Star Inc., Ashland, p. 37.
2. Barabas K., Milner R., Lurie D., Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet. Comp. Oncol. 2008, 6:1-18.
3. Bozic M., de Rooij J., Parisi E., Ortega M.R., Fernandez E., Valdivielso J.M. Glutamatergic signaling maintains the epithelial phenotype of proximal tubular cells. J. Am. Soc. Nephrol. 2011, 22:1099-1111.
4. Bucaloiu I.D., Kirchner H.L., Norfolk E.R., Hartle J.E., Perkins R.M. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int. 2012, 81:477-485.
5. Bunel V., Antoine M.H., Nortier J., Duez P., Stevigny C. Potential nephroprotective effects of the Chinese herb Angelica sinensis against cisplatin tubulotoxicity. Pharm. Biol. 2014, [Epub ahead of print]. 10.3109/13880209.2014.951726.
6. Bunel V., Antoine M.H., Nortier J., Duez P., Stevigny C. Protective effects of schizandrin and schizandrin B towards cisplatin nephrotoxicity in vitro. J. Appl. Toxicol. 2014, 34:1311-1319.
7. Cai Q., Li X., Wang H. Astragali and Angelica protect the kidney against ischemia and reperfusion injury and accelerate recovery. Chin. Med. J. (Engl.) 2001, 114:119-123.
8. Chao W.W., Lin B.F. Bioactivities of major constituents isolated from Angelica sinensis (Danggui). Chin. Med. 2011, 6:1-7.
9. Chen X.P., Li W., Xiao X.F., Zhang L.L., Liu C.X. Phytochemical and pharmacological studies on Radix Angelicae sinensis. Chin. J. Nat. Med. 2013, 11:577-587.
10. Cummings B.S., Schnellmann R.G. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 2002, 302:8-17.
11. Davis C.A., Nick H.S., Agarwal A. Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J. Am. Soc. Nephrol. 2001, 12:2683-2690.
12. Docherty N.G., O'Sullivan O.E., Healy D.A., Murphy M., O'Neill A.J., Fitzpatrick J.M., Watson R.W. TGF-beta1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am. J. Physiol. Renal. Physiol. 2006, 290:F1202-F1212.
13. dos Santos N.A., Carvalho Rodrigues M.A., Martins N.M., dos Santos A.C. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch. Toxicol. 2012, 86:1233-1250.
14. Geback T., Schulz M.M., Koumoutsakos P., Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques 2009, 46:265-274.
15. Gottardi C.J., Gumbiner B.M. Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes. J. Cell Biol. 2004, 167:339-349.
16. Hao S., He W., Li Y., Ding H., Hou Y., Nie J., Hou F.F., Kahn M., Liu Y. Targeted inhibition of b-catenin/CBP signaling ameliorates renal interstitial fibrosis. J. Am. Soc. Nephrol. 2011, 22:1642-1653.
17. Havasi A., Borkan S.C. Apoptosis and acute kidney injury. Kidney Int. 2011, 80:29-40.
18. He W., Kang Y.S., Dai C., Liu Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J. Am. Soc. Nephrol. 2011, 22:90-103.
19. Hilal G., Albert C., Vallée M. Mécanismes impliqués dans la néphrotoxicité. Ann. Biol. Clin. Qué. 2005, 42:29-35.
20. Hsiao C.Y., Hung C.Y., Tsai T.H., Chak K.F. A study of the wound healing mechanism of a traditional Chinese Medicine, Angelica sinensis, using a proteomic approach. Evid. Based Complement Alternat. Med. 2012, 2012:1-14.
21. Hu Q., Noor M., Wong Y.F., Hylands P.J., Simmonds M.S., Xu Q., Jiang D., Hendry B.M. In vitro anti-fibrotic activities of herbal compounds and herbs. Nephrol. Dial. Transplant. 2009, 24:3033-3041.
22. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999, 99:2467-2498.
23. Junqueira L.C., Bignolas G., Brentani R.R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 1979, 11:447-455.
24. Kaushal G.P., Kaushal V., Herzog C., Yang C. Autophagy delays apoptosis in renal tubular epithelial cells in cisplatin cytotoxicity. Autophagy 2008, 4:710-712.
25. Lee S.B., Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int. 2010, 78:S22-S26.
26. Li X., Wang H. Chinese herbal medicine in the treatment of chronic kidney disease. Adv. Chronic Kidney Dis. 2005, 12:276-281.
27. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol. 2010, 21:212-222.
28. Low Dog T. Menopause: a review of botanical dietary supplements. Am. J. Med. 2005, 118(Suppl 12B):98-108.
29. Mancuso C., Santangelo R. Ferulic acid: pharmacological and toxicological aspects. Food Chem. Toxicol. 2014, 65:185-195.
30. Megyesi J., Andrade L., Vieira J.M., Safirstein R.L., Price P.M. Coordination of the cell cycle is an important determinant of the syndrome of acute renal failure. Am. J. Physiol. Renal. Physiol. 2002, 283:F810-F816.
31. Meng L.Q., Tang J.W., Wang Y., Zhao J.R., Shang M.Y., Zhang M., Liu S.Y., Qu L., Cai S.Q., Li X.M. Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy. Br. J. Pharmacol. 2011, 162:1805-1818.
32. Nortier J., Sculier J.P. Thoracic malignancies, cisplatin and renal function. Eur. Respir. J. 2011, 37:760-761.
33. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73:994-1007.
34. Pape L., Henne T., Offner G., Strehlau J., Ehrich J.H., Mengel M., Grimm P.C. Computer-assisted quantification of fibrosis in chronic allograft nephropaty by picosirius red-staining: a new tool for predicting long-term graft function. Transplantation 2003, 76:955-958.
35. Peng B., Zhao P., Lu Y.P., Chen M.M., Sun H., Wu X.M., Zhu L. Z-ligustilide activates the Nrf2/HO-1 pathway and protects against cerebral ischemia-reperfusion injury in vivo and in vitro. Brain Res. 2013, 1520:168-177.
36. Pozdzik A.A., Salmon I.J., Debelle F.D., Decaestecker C., Van Den Branden C., Verbeelen D., Deschodt-Lanckman M.M., Vanherweghem J.L., Nortier J.L. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int. 2008, 73:595-607.
37. Puchtler H., Waldrop F.S., Valentine L.S. Polarization microscopic studies of connective tissue stained with picro-sirius red FBA. Beiträge zur Pathol. 1973, 150:174-187.
38. Ryan M.J., Johnson G., Kirk J., Fuerstenberg S.M., Zager R.A., Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int. 1994, 45:48-57.
39. Saw C.L., Wu Q., Su Z.Y., Wang H., Yang Y., Xu X., Huang Y., Khor T.O., Kong A.N. Effects of natural phytochemicals in Angelica sinensis (Danggui) on Nrf2-mediated gene expression of phase II drug metabolizing enzymes and anti-inflammation. Biopharm. Drug Dispos. 2013, 34:303-311.
40. Song J., Meng L., Li S., Qu L., Li X. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, improved renal microvascular insufficiency in 5/6 nephrectomized rats. Vascul. Pharmacol. 2009, 50:185-193.
41. Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. 2005, 23:7212-7220.
42. Valcu M., Valcu C.M. Data transformation practices in biomedical sciences. Nat. Methods 2011, 8:104-105.
43. Wang H., Li J., Yu L., Zhao Y., Ding W. Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin amino nucleoside nephrosis. Life Sci. 2004, 74:1645-1658.
44. Wojcikowski K., Wohlmuth H., Johnson D.W., Rolfe M., Gobe G. An in vitro investigation of herbs traditionally used for kidney and urinary system disorders: potential therapeutic and toxic effects. Nephrology 2009, 14:70-79.
45. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 2007, 117:524-529.
46. Wynn T.A. Fibrosis under arrest. Nat. Med. 2010, 16:523-525.
47. Xu Q., Norman J.T., Shrivastav S., Lucio-Cazana J., Kopp J.B. In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of antifibrotic agents. Am. J. Physiol. Renal Physiol. 2007, 293:F631-F640.
48. Yang J.-Y., Chen H.-H., Wu J., Gong S.-X., Chen C.-Q., Zhang T.-J., Wang M.-J. Advances in studies on pharmacological functions of ligustilide and their mechanisms. Chinese Herbal Med. 2012, 4:26-32.
49. Yang L., Besschetnova T.Y., Brooks C.R., Shah J.V., Bonventre J.V. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat. Med. 2010, 16:535-543. (531p following 143).
50. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007, 334:115-124.
51. Zeisberg M., Duffield J.S. Resolved: EMT produces fibroblasts in the kidney. J. Am. Soc. Nephrol. 2010, 21:1247-1253.
52. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119:1429-1437.